nifedipine has been researched along with Mitral Incompetence in 15 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect on myocardial function and structure of long-term administration of quinapril (10-20 mg daily), an angiotensin-converting-enzyme (ACE) inhibitor, was investigated in 24 patients (18 men, 6 women; mean age 48 [20-65] years) with chronic isolated asymptomatic aortic or mitral regurgitation." | 1.29 | [Long-term treatment with quinapril in chronic aortic and mitral insufficiency]. ( Schömig, A; Schön, HR, 1995) |
| "An additional 6 dogs with mitral regurgitation were followed for 30 min without nifedipine (group 3)." | 1.27 | Mechanisms for improvement of cardiac performance by nifedipine in an acute mitral regurgitation in dogs. ( Ito, T; Matsumoto, S; Okabe, F; Sohara, H; Ueda, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (40.00) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, N | 1 |
| Dalmia, S | 1 |
| Deka, D | 1 |
| Mittal, S | 1 |
| Cantelli, I | 1 |
| Pavesi, PC | 1 |
| Parchi, C | 1 |
| Naccarella, F | 1 |
| Bracchetti, D | 1 |
| Rousseau, MF | 1 |
| Pouleur, H | 1 |
| Charlier, AA | 1 |
| Brasseur, LA | 1 |
| Fournier Andray, JA | 1 |
| Cubero García, J | 1 |
| Schön, HR | 2 |
| Schömig, A | 1 |
| Röthlisberger, C | 1 |
| Sareli, P | 1 |
| Wisenbaugh, T | 1 |
| Cacciapuoti, F | 1 |
| Perrone, N | 1 |
| Diaspro, R | 1 |
| Galzerano, D | 1 |
| Gentile, S | 1 |
| Lapiello, B | 1 |
| Lee, JM | 1 |
| Masuyama, T | 1 |
| Nagano, R | 1 |
| Yamamoto, K | 1 |
| Nariyama, K | 1 |
| Tanouchi, J | 1 |
| Hori, M | 1 |
| Kamada, T | 1 |
| Kelbaek, H | 1 |
| Aldershvile, J | 1 |
| Skagen, K | 1 |
| Hildebrandt, P | 1 |
| Nielsen, SL | 1 |
| Grayburn, PA | 1 |
| Zhilin, SV | 1 |
| Vorob'ev, BI | 1 |
| Kastanaian, AA | 1 |
| Masalitinova, IV | 1 |
| Dyszkiewicz, W | 1 |
| Ponizyński, A | 1 |
| Sarnowski, W | 1 |
| Biczysko, W | 1 |
| Kaczmarek, J | 1 |
| Okabe, F | 1 |
| Sohara, H | 1 |
| Ueda, A | 1 |
| Ito, T | 1 |
| Matsumoto, S | 1 |
| Kimchi, A | 1 |
| Ellrodt, AG | 1 |
| Charuzi, Y | 1 |
| Shell, W | 1 |
| Murata, GH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| The Study to Define the Unique Molecular Mechanisms of Mitral Regurgitation in Order to Find New Targeted Therapy to Attenuate the Remodeling and Delay the Need for Surgery and Improve Surgical Outcomes.[NCT01052532] | 65 participants (Actual) | Observational | 2005-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
2 reviews available for nifedipine and Mitral Incompetence
| Article | Year |
|---|---|
Medical treatment of chronic valvular regurgitation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Insufficiency; Chronic Disease; Humans; Isoqu | 1995 |
Vasodilator therapy for chronic aortic and mitral regurgitation.
Topics: Aortic Valve Insufficiency; Chronic Disease; Digoxin; Heart Ventricles; Hemodynamics; Humans; Mitral | 2000 |
4 trials available for nifedipine and Mitral Incompetence
| Article | Year |
|---|---|
Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation.
Topics: Adult; Captopril; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Hemodynamics; | 1994 |
Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation.
Topics: Adult; Captopril; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Hemodynamics; | 1994 |
Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation.
Topics: Adult; Captopril; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Hemodynamics; | 1994 |
Comparison of single dose nifedipine and captopril for chronic severe mitral regurgitation.
Topics: Adult; Captopril; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Hemodynamics; | 1994 |
Slowing of mitral valve annular calcium in systemic hypertension by nifedipine and comparisons with enalapril and atenolol.
Topics: Adult; Atenolol; Calcinosis; Echocardiography, Doppler; Enalapril; Female; Heart Valve Diseases; Hum | 1993 |
Pre- and afterload reduction in chronic mitral regurgitation: a double-blind randomized placebo-controlled trial of the acute and 2 weeks' effect of nifedipine or isosorbide dinitrate treatment on left ventricular function and the severity of mitral regur
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Blood Pressure; Chronic Disease; Doub | 1996 |
[Differential use of peripheral vasodilators in the treatment of chronic circulatory failure in patients with mitral valve insufficiency].
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Hydralazine; | 1990 |
9 other studies available for nifedipine and Mitral Incompetence
| Article | Year |
|---|---|
Successful maternal and fetal outcome in a pregnancy with type V Takayasu's aortoarteritis.
Topics: Adult; Antihypertensive Agents; Arterial Occlusive Diseases; Calcium Channel Blockers; Diuretics; Fe | 2008 |
Acute hemodynamic effects of combined therapy with digoxin and nifedipine in patients with chronic heart failure.
Topics: Aged; Blood Pressure; Cardiac Output; Digoxin; Drug Therapy, Combination; Female; Heart Failure; Hem | 1983 |
Assessment of left ventricular relaxation in patients with valvular regurgitation.
Topics: Adult; Aged; Aortic Valve Insufficiency; Cardiac Catheterization; Cineangiography; Female; Heart Ven | 1982 |
[Hemodynamic effect of nifedipine in left valvular diseases with volumetric overload].
Topics: Adolescent; Adult; Aortic Valve Insufficiency; Female; Hemodynamics; Humans; Male; Middle Aged; Mitr | 1982 |
[Long-term treatment with quinapril in chronic aortic and mitral insufficiency].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Insufficiency; Chronic Disease; | 1995 |
Effects of vasodilators on pulmonary venous and mitral flow velocity patterns in patients with congestive heart failure.
Topics: Adult; Aged; Blood Flow Velocity; Echocardiography, Doppler; Female; Heart Failure; Humans; Isosorbi | 1993 |
[Protective effect of nifedipine on myocardial mitochondria during the surgical treatment of mitral valve defects].
Topics: Cardioplegic Solutions; Drug Synergism; Heart Arrest, Induced; Humans; Intraoperative Care; Mitochon | 1987 |
Mechanisms for improvement of cardiac performance by nifedipine in an acute mitral regurgitation in dogs.
Topics: Animals; Blood Pressure; Coronary Circulation; Dogs; Heart Rate; Hemodynamics; Mitral Valve Insuffic | 1985 |
Salutary hemodynamic and sustained clinical beneficial effects of nisoldipine, a new calcium channel blocker, in patients with recurrent ischemia and severe heart failure.
Topics: Aged; Calcium Channel Blockers; Coronary Disease; Heart Failure; Hemodynamics; Humans; Male; Mitral | 1985 |